Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells

• Published in: Scientific reports Vol. 11; no. 1; pp. 22195 - 14
• Main Authors: Caohuy, Hung, Eidelman, Ofer, Chen, Tinghua, Liu, Shufeng, Yang, Qingfeng, Bera, Alakesh, Walton, Nathan I., Wang, Tony T., Pollard, Harvey B.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 12.11.2021; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/556; 631/92/609; 692/699/1785/4039; A549 Cells; ACE2; Angiotensin-converting enzyme 2; Angiotensin-Converting Enzyme 2 - metabolism; Animals; Cardiac glycosides; Cardiotonic Agents - pharmacology; Chlorocebus aethiops; COVID-19; COVID-19 - metabolism; COVID-19 Drug Treatment; Digitoxin - pharmacology; Digoxigenin; Digoxin; Digoxin - pharmacology; Glycosides; Humanities and Social Sciences; Humans; Infectivity; Lung - drug effects; Lung - metabolism; multidisciplinary; Ouabain; Ouabain - pharmacology; Protein Binding - drug effects; Proteins; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Science; Science (multidisciplinary); Severe acute respiratory syndrome coronavirus 2; Spike Glycoprotein, Coronavirus - metabolism; Spike protein; Vero Cells; Virus Internalization - drug effects
• DOI: 10.1038/s41598-021-01690-9
• ISSN: 2045-2322

To initiate SARS-CoV-2 infection, the Receptor Binding Domain (RBD) on the viral spike protein must first bind to the host receptor ACE2 protein on pulmonary and other ACE2-expressing cells. We hypothesized that cardiac glycoside drugs might block the binding reaction between ACE2 and the Spike (S) protein, and thus block viral penetration into target cells. To test this hypothesis we developed a biochemical assay for ACE2:Spike binding, and tested cardiac glycosides as inhibitors of binding. Here we report that ouabain, digitoxin, and digoxin, as well as sugar-free derivatives digitoxigenin and digoxigenin, are high-affinity competitive inhibitors of ACE2 binding to the Original [D614] S1 and the α/β/γ [D614G] S1 proteins. These drugs also inhibit ACE2 binding to the Original RBD, as well as to RBD proteins containing the β [E484K], Mink [Y453F] and α/β/γ [N501Y] mutations. As hypothesized, we also found that ouabain, digitoxin and digoxin blocked penetration by SARS-CoV-2 Spike-pseudotyped virus into human lung cells, and infectivity by native SARS-CoV-2. These data indicate that cardiac glycosides may block viral penetration into the target cell by first inhibiting ACE2:RBD binding. Clinical concentrations of ouabain and digitoxin are relatively safe for short term use for subjects with normal hearts. It has therefore not escaped our attention that these common cardiac medications could be deployed worldwide as inexpensive repurposed drugs for anti-COVID-19 therapy.